
|Articles|August 4, 2003
Many could benefit from BPH drug with unique technology
Men with benign prostatic hyperplasia (BPH) will soon have a therapeutic option that uses a unique drug delivery system. The FDA recently approved alfuzosin (UroXatral, Sanofi-Synthelabo) extended-release tablets for the treatment of the signs and symptoms of BPH. Alfuzosin is not indicated for the treatment of hypertension. The manufacturer expects alfuzosin to be available in pharmacies sometime in the second half of 2003.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Once Weekly Oral HIV Regimen Maintains Suppression Through Week 48
2
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
3
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
4
ASHP Adopts New Policies Around Misinformation and Vaccine Access Gaps
5




























